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ABSTRACT
Introduction Human respiratory syncytial virus (HRSV) 
is a common cause of respiratory tract infections (RTIs) 
globally and is one of the most fatal infectious diseases 
for infants in developing countries. Of those infected, 
25%–40% aged ≤1 year develop severe lower RTIs 
leading to pneumonia and bronchiolitis, with ~10% 
requiring hospitalisation. Evidence also suggests that 
HRSV infection early in life is a major cause of adult 
asthma. There is no HRSV vaccine, and the only clinically 
approved treatment is immunoprophylaxis that is 
expensive and only moderately effective. New anti- HRSV 
therapeutic strategies are therefore urgently required.
Methods It is now established that viruses require 
cellular ion channel functionality to infect cells. Here, 
we infected human lung epithelial cell lines and ex 
vivo human lung slices with HRSV in the presence of a 
defined panel of chloride (Cl−) channel modulators to 
investigate their role during the HRSV life- cycle.
Results We demonstrate the requirement for 
TMEM16A, a calcium- activated Cl− channel, for HRSV 
infection. Time- of- addition assays revealed that the 
TMEM16A blockers inhibit HRSV at a postentry stage of 
the virus life- cycle, showing activity as a postexposure 
prophylaxis. Another important negative- sense RNA 
respiratory pathogen influenza virus was also inhibited 
by the TMEM16A- specific inhibitor T16Ainh- A01.
Discussion These findings reveal TMEM16A as 
an exciting target for future host- directed antiviral 
therapeutics.
INTRODUCTION
Human respiratory syncytial virus (HRSV) is one 
of the most significant causes of respiratory tract 
infections worldwide. The greatest risk factor for 
HRSV- related disease is age, with 95% of chil-
dren becoming infected before the age of 2 years 
and an increased susceptibility in those aged over 
65 years.1 2 The developing morphology of infant 
airways increases the severity of symptoms, as 
their narrower bronchioles are more susceptible 
to HRSV- induced inflammation.3 As a result, 
25%–40% of infants with lower respiratory tract 
infections develop bronchiolitis or pneumonia and 
~10% require hospitalisation, where they receive 
supplemental oxygen or intubation to improve 
ventilation. HRSV causes ~1 99 000 deaths per 
year, 99% of which occur in developing countries.2 
The virus also imposes a heavy financial burden on 
healthcare systems and is an under- recognised cause 
of morbidity in the elderly.1 Diagnostic testing is 
not recommended in routine cases and treatment 
is supportive.4 Certain high- risk groups of children 
that test positive may receive ribavirin, the efficacy 
of which is questionable.4 5 Immunoprophylaxis 
with palivizumab is also available, but its effective-
ness is moderate, and its expense limits its adminis-
tration.4 No antiviral drugs to treat HRSV infection 
are currently available in the clinic.
HRSV is an orthopneumovirus within the family 
Pneumoviridae, a large and diverse grouping of 
non- segmented negative- sense single- stranded RNA 
(- ssRNA) viruses.6 HRSV particles are pleomorphic, 
adopting spherical, filamentous and asymmetric 
forms that vary from 100 to 1000 nm in size.7 The 
HRSV genome encodes 10 genes (3′-NS1- NS2- N- 
P- M- SH- G- F- M2- L-5′) that are tightly encapsidated 
by the nucleoprotein (N) to form a helical nucleo-
capsid.8 Mature virions possess a host- derived lipid 
envelope containing three structural proteins: the 
glycoprotein (G), fusion protein (F) and a small 
hydrophobic protein (SH), which form individual 
protruding spikes. The matrix protein (M) lies on 
the internal interface of the envelope and acts as 
a bridge connecting the structural transmembrane 
proteins to N bound to the RNA genome.7 The 
Key messages
What is the key question?
 ► If we can identify a new druggable cellular 
target to inhibit human respiratory syncytial 
virus (HRSV).
What is the bottom line?
 ► The current COVID-19 pandemic has 
highlighted the ever- present need for front- line 
antiviral therapeutics, and no effective vaccines 
or drugs for HRSV are currently available.
Why read on?
 ► We reveal the ability to inhibit HRSV with Cl− 
channel modulators, highlighting their promise 
as anti- HRSV therapeutics with the potential for 
drug repurposing.
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binding of RNA with multiple copies of N forms the charac-
teristic ribonucleocapsids, which in turn interact with the 
phosphoprotein (P) and the large polymerase (L) to form the 
ribonucleoprotein (RNP) complex, the fundamental machinery 
required for HRSV transcription and replication.8
One strategy to prevent HRSV infection is to target key virus–
host interactions that are essential for virus multiplication. Ion 
channels are emerging as key factors required during virus repli-
cative cycles, examples including the roles for potassium (K+) 
channels in Bunyamwera virus (BUNV) infection9 10; two- pore 
calcium (Ca2+) channels in Ebola virus (EBOV) infection11 and 
chloride (Cl−) channels in chikungunya virus (CHIKV), hepatitis 
C virus (HCV), BK polyomavirus and Merkel cell polyomavirus 
infection.12–15 Cl− channels are diverse families of proteins that 
regulate cell excitability and fluid and osmolyte secretion in lung 
epithelial cells. Over 40 genes are linked to Cl− conductances 
which can be categorised into voltage- gated Cl− channels (ClC), 
ligand- gated Cl- channels, cystic fibrosis transmembrane conduc-
tance regulator (CFTR), volume- regulated anion channels and 
Ca2+- activated Cl− channel (CaCC) families.16
Herein, we reveal that a new host factor TMEM16A/ANO1, 
a calcium- activated Cl− channel, is required during HRSV infec-
tion. We propose that targeting TMEM16A Cl− conductances 
may represent a new and pharmacologically safe therapeutic 
strategy for this important human pathogen.
MATERIALS AND METHODS
Cell culture and virus strains
A549 (adenocarcinoma human alveolar basal epithelial cells), 
HEp-2 (human epithelial cells) and SH- SY5Y (human neuro-
blastoma cells) were cultured at 37°C, 5% CO2 in Dulbecco's 
Modified Eagle's Medium (DMEM, Sigma) supplemented 
with 10% FBS and penicillin/streptomycin (P/S, 100 U/mL and 
100 µg/mL, respectively). Wild type HRSV- A2 was obtained 
from the National Collection of Pathogenic Viruses (NCPV) of 
Public Health England (PHE). HRSV- GFP was purchased from 
ViraTree (HRSV- GFP). GFP- PA- labelled influenza A virus (IAV- 
GFP) was rescued as previously described.17
Plaque assays
HEp-2 monolayers were infected with serially diluted virus and 
overlayed with 1.6% methylcellulose (Sigma, 1500 cP): DMEM 
(10% FBS, 1% P/S) prior to incubation at 37°C for 5 days. Cells 
were washed, fixed in 80% methanol and blocked in 5% milk 
in phosphate- buffered saline, 0.1% tween 20 detergent (PBS- 
T). Plaques were detected using goat α-HRSV (Abcam ab20745, 
1:200) and HRP- conjugated rabbit α-goat (Sigma A8919, 1:5000) 
and imaged following incubation with 4- chloro-1- naphthol (4- CN, 
Pierce, 1:10) and 30% H2O2 (Sigma).
Cl− channel inhibitor assays
A549 or SH- SY5Y cells (1×104 cells/well) in 96 wells were 
pretreated with the indicated Cl− channel blockers and infected 
with HRSV- GFP (MOI: 0.1) in the presence of each inhibitor 
for 24 hours. HRSV- GFP fluorescence was visualised using an 
IncuCyte ZOOM imager (IncuCyte, Essen Bioscience). Fluores-
cence was quantified using accompanying analysis software. The 
Cl− channel modulators used in the study were as follows: broad- 
spectrum Cl− channel inhibitors 5- nitro-2-(3- phenylpropylamino) 
benzoic acid (NPPB—Sigma- Aldrich, N4779), 4,4ʹ-diisothiocya-
nostilbene-2,2ʹ-disulfonic acid (DIDS—Sigma- Aldrich, D3514) and 
R(+)-[(6,7- Dichloro-2- cyclopentyl-2,3- dihydro-2- methyl-1- oxo- 
1H- inden-5- yl)- oxyacetic acid (R+IAA-94—Sigma- Aldrich, I117); 
CFTR inhibitors: CFTRinh-172 (Sigma- Aldrich, C2992), chro-
manol 293B (Sigma- Aldrich, C2615) and glibenclamide (Tocris 
Biosciences, 0911); CaCC inhibitors: CaCCinh- A01 (Sigma- 
Aldrich, SML0916), niflumic acid (Sigma- Aldrich, N0630), talni-
flumate (Sigma- Aldrich, SML1710) and tannic acid (Sigma- Aldrich, 
403040); TMEM16A inhibitors: T16Ainh- A01 (Merck Chemi-
cals, 613551) and MONNA (Sigma- Aldrich, SML0902). Ribavirin 
(Sigma- Aldrich, R9644) was included as a known HRSV inhibitor.
Cell viability assays
For viability assessments, drug- treated cells were incubated with 
CellTiter96 AQueous One Solution (Promega) at 37°C for 1 hour. 
Absorbances were measured at 492 nm on a microplate reader.
Time of addition assays
A549 cells (1×104 cells/well) in 96- well plates were treated with 
inhibitors prepared at 2× working concentrations in DMEM 
(2% FBS, 1% P/S) and an equal volume of HRSV- GFP super-
natant (MOI 0.1, T=0). For postinfection treatments, drugs 
were added at 3, 6 or 9 hours postinfection (hpi). HRSV- GFP 
expression was assessed via IncuCyte analysis at 24 hpi (eg, when 
added at 9 hpi, the inhibitor contacted the cells for 15 hours 
prior to the analysis of GFP expression).
Virion treatments
Channel inhibitors were prepared to 2× working concentrations in 
DMEM (2% FBS, 1% P/S) and directly added to an equal volume of 
HRSV MOI 0.2 for 45 min at room temperature. The virus/inhib-
itor mix was then diluted into media (3 mL per well) and added to 
A549 cells for 24 hours (MOI 0.2; final inhibitor concentration on 
cells ≥400- fold dilution from active concentration). HRSV gene 
expression was assessed via western blotting.
Western blot analysis
Cells were harvested in lysis buffer (25 mM glycerol phosphate, 
20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton, 10% glyc-
erol, 50 mM NaF, 5 mM Na4O7P2—pH 7.4) supplemented with 
halt protease inhibitor cocktail (Thermo Scientific). Lysates were 
resolved on sodium dodecyl sulfate- polyacrylamide (SDS- PAGE) 
gels and transferred to methanol- activated polyvinylidene diflu-
oride membranes (Millipore) using a Trans- Blot Turbo Transfer 
System (Bio- Rad). Membranes were blocked in 10% (w/v) milk 
in TBS- T and probed with the appropriate primary antibodies 
(goat α-HRSV (Abcam ab20745, 1:1000); mouse α-GAPDH 
(Santa Cruz sc47724, 1:1000)) in 5% milk. Membranes were 
labelled with HRP- conjugated secondary antibodies (Sigma: goat 
α-mouse (Sigma A4416, 1:5000); rabbit α-goat (Sigma A8919, 
1:5000)) in 5% milk and target proteins were detected using the 
enhanced chemiluminescence system (Advansta) and developed 
on CL- Xposure film using an Xograph processor. Densitometry 
was performed using ImageJ.
IncuCyte analysis
An IncuCyte ZOOM instrument (IncuCyte) and accompanying 
software (2018A) were used to analyse HRSV- GFP fluorescence. 
Plates were scanned using the 10× objective in both the phase 
and green channels. The processing definition was set on an 
individual basis using top- hat background subtraction, threshold 
(GCU), radius (µM), edge sensitivity and area filter (µm2). The 
total green object count (1/well) or the average integrated inten-
sity (GCU × µm2) were recorded.
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Preparation of precision-cut lung slices
Primary human lung tissue was provided by KRH Klinikum Siloah- 
Oststadt- Heidehaus (Hanover, Germany) from patients with 
cancer who underwent lung resection. Samples were provided 
from ≥3 donors. Human precision- cut lung slices (PCLS) were 
generated from disease- free tissue as previously described.18 Briefly, 
lobes were filled with 2% agarose (Sigma- Aldrich) in DMEM/F12 
(Gibco) via the bronchi. Solidified tissue was punched into cores of 
8 mm diameter and cut into slices of 300–350 µm on a microtome 
(Krumdieck Tissue Slicer, Alabama Research and Development, 
Munford, Alabama, USA). PCLS containing airways were micro-
scopically checked for ciliary movement and cultured in 24- well 
plates in DMEM/F12 supplemented with 1 % P/S (10 000 U/mL, 
Gibco) at 37°C with 5% CO2 overnight.
Ex vivo infection experiments using human PCLS
PCLS were drug- treated for 40 min in DMEM/F12 (1% P/S) 
and subsequently infected with HRSV (106 pfu/mL) or UV- in-
activated virus. Supernatants were collected after 24 hours, 
and tissues were lysed in 1% Triton X-100 (Sigma- Aldrich) in 
PBS (Lonza). Supernatants and lysates were supplemented with 
0.02% Protease Inhibitor Cocktail (P1860, Sigma- Aldrich). For 
viability assessments, lactate dehydrogenase (LDH) release was 
assayed in the supernatants using Cytotoxicity Detection Kits 
(Roche). Interferon gamma- induced protein 10 (IP-10) secretion 
was measured using the Human CXCL10/IP-10 ELISA DuoSet 
(R&D Systems). Total protein content was measured via BCA 
assay (Thermo Scientific). Virus protein production was assessed 
by western blotting.
For immunofluorescent analysis, human airway containing 
PCLS were inoculated with 106 pfu/mL HRSV for 2 hours and 
subsequently cultivated for 72 hours. After fixation in 2% para-
formaldehyde, tissues were permeabilised with 0.3% Triton 
X-100 and blocked in 4% donkey serum prior to probing for 
HRSV (Goat IgG polyclonal to respiratory syncytial virus, 
Abcam, ab20745; 1:200) and for ARL13B (Cilia; Rabbit IgG 
polyclonal to ARL13B, Proteintech Group, 17 711-1- AP; 1:300) 
and staining with the appropriate secondary antibodies (Cy5 
AffiniPure Donkey Anti- Goat IgG (H+L); Jackson ImmunoRe-
search, 705-176-147; 1:1000; Cy2 AffiniPure Donkey Anti- 
Rabbit IgG (H+L); Jackson ImmunoResearch, 711-225-152; 
1:1000). Nuclei were stained with DAPI. Immunofluorescence 
imaging was performed on a confocal laser scanning microscope 
(Zeiss, LSM 800).
Statistical analysis
Total green object count (1/well), average integrated intensity 
(GCU × µm2), western blot densitometry and cell viability data 
were compared using a one- way analysis of variance (ANOVA) 
Bonferroni multiple comparison test (Cl− channel inhibitor- treated 
cells vs solvent- treated controls). Data were analysed using Micro-
soft Excel (V.2013). Assays were verified using the known HRSV 
inhibitor ribavirin. P values ≤0.05 were considered statistically 
significant (*) and are shown in supplemental file 3). For PCLS 
data, statistical analysis was performed using a one- way ANOVA 
Dunnett’s multiple comparison test or an unpaired Mann- Whitney 




For drug assays, we used a commercially available recombinant 
HRSV A2 variant (HRSV- GFP) that expresses eGFP from an 
independent transcriptional unit located in the promoter- proximal 
position. In A549 cells infected with HRSV- GFP, GFP was quanti-
fiable ≥9 hpi (figure 1A) as assessed via live- cell IncuCyte analysis, 
consistent with the time course of WT- HRSV A2 gene expression 
previously reported in this cell line.19 HRSV- GFP- infected cells 
showed HRSV antigen positivity when stained with α-HRSV anti-
bodies (figure 1B). Titres of the HRSV- GFP virus were comparable 
with those of the parental WT- HRSV A2 strain and produced an 
identical plaque morphology (figure 1C). HRSV- GFP infection was 
also inhibited by ribavirin, a known HRSV inhibitor (figure 1D), 
evidenced by the significant loss of HRSV- GFP fluorescence 
versus no- drug cells. These data confirmed the suitability of the 
HRSV- GFP system as a rapid and quantifiable method to identify 
inhibitory compounds against HRSV.
Figure 1 Establishment of HRSV- GFP assays. (A) Time course of GFP 
expression in A549 cells infected with HRSV- GFP at MOI 0.1 (dashed 
line) and MOI 1 (solid line). (B) IncuCyte images of A549 cells infected 
with HRSV- GFP and co- stained with α-HRSV (red). (C) Comparison of 
WT- HRSV (left) and HRSV- GFP (right) plaques at a dilution factor of 
10−4. (D(i)) Analysis of HRSV- GFP expression in A549 cells pretreated 
with increasing concentrations of ribavirin. Values are normalised 
to (H2O) control cells (GFP count per well—black bars). Relative cell 
viability (grey bars) determined via MTS assay. Experiments were 
performed in duplicate in 96- well plates and represent the average 
of four independent repeats (n=4)±SE. Independent replicates 
refer to repeat experiments performed on separate days using new 
batches of cells, drug and virus stocks to confirm reproducibility. 
Statistical significance p<0.05 is represented by an asterisk (*). (D(ii)) 
Representative IncuCyte ZOOM images of A549 cells treated with 
increasing concentrations of ribavirin (left to right) and infected with 
HRSV- GFP. Scale bar: 300 µm. HRSV,human respiratory syncytial virus; 
WT, wild type.
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Blocking Cl− channels inhibits HRSV
Cl− channels are key regulators of transepithelial Cl− transport 
and fluid secretion in lung cells.16 To investigate their role during 
HRSV infection, we first assessed the effects of well- characterised 
broad- spectrum Cl− channel blockers including DIDS, NPPB 
and R+IAA-94 for their effects on HRSV (figure 2A–C, black 
bars, figure 2D). The addition of DIDS (10–50 µM) decreased 
HRSV- GFP expression in a concentration- dependent manner 
versus no- drug controls (62%–86% inhibition, figure 2A). A 
similar effect was observed following treatment with NPPB 
(40–100 µM, 43%–95% inhibition, figure 2B). In contrast, 
R+IAA-94 (5–25 µM), a more specific blocker of CLIC chan-
nels, had no effect on HRSV- GFP expression (figure 2C). At 
all concentrations assessed, the compounds were non- toxic as 
confirmed by MTS assays (figure 2A–C, grey bars). For confir-
mation of these data, WT- HRSV gene expression was assessed 
through western blotting of cell lysates for HRSV- G, a loss of 
which was observed in cells treated with ribavirin, DIDS and 
NPPB, while R+IAA-94 had no effect (figure 2E). These data 
were further confirmed in SH- SY5Y cells, a human neuronal 
cell- line permissive to HRSV20 (figure 2F). Taken together, these 
data suggest that HRSV infection is dependent on the function 
of a DIDS/NPPB- sensitive, R+IAA-94- insensitive Cl− channel to 
efficiently infect cells.
Inhibiting CFTR does not influence HRSV infection
The primary target for HRSV infection is the respiratory tract, 
in which the functions of CFTR are well- characterised.21 We 
therefore investigated the effects of specific CFTR inhibitors 
on HRSV infection using CFTR(inh)-172, chromanol 293B and 
glibenclamide. Treatment with each of the CFTR inhibitors had 
no effect on HRSV- GFP expression compared with no- drug 
controls (figure 3A–D). Given that these drugs failed to recapitu-
late the effects of either DIDS or NPPB, we reasoned that HRSV 
does not require CFTR activity during its infectious life- cycle.
Blocking CaCCs inhibits HRSV infection
Several specific CaCC inhibitors are available, including 
CaCCinh- A01, niflumic acid, talniflumate and tannic acid22–24 
(figure 4A). When A549 cells were infected in the presence of 
each of these compounds, a significant, concentration- dependent 
reduction in HRSV- GFP infection was observed at non- cytotoxic 
concentrations (figure 4B–F). A similar concentration- dependent 
loss of HRSV- G expression was observed in cells infected with 
WT- HRSV in the presence of each modulator, as assessed by 
western blotting (figure 4G–J). These data implicated a require-
ment for CaCC activity during HRSV infection.
Figure 2 Broad- spectrum Cl− channel inhibitors DIDS and NPPB 
decrease HRSV- GFP infection. (A–C) HRSV- GFP expression in A549 cells 
pretreated with broad- spectrum Cl− channel inhibitors DIDS (10–50 µM), 
NPPB (40–100 µM) and R+IAA-94 (10–25 µM), shown as a percentage 
of DMSO control cells (GFP count per well—black bars). Cell viability in 
each condition was determined via MTS assay (grey bars). Experiments 
were performed in duplicate in 96- well plates and represent the average 
of four independent repeats (n=4)±SE. p<0.05 is represented by an 
asterisk (*). (D) Representative Incucyte images of A549 cells treated 
with increasing concentrations of DIDS, NPPB and R+IAA-94 (left to 
right) and infected with HRSV- GFP. Images taken using IncuCyte ZOOM 
software. Scale bar: 300 µm. (E–F) Western blot analysis of wild type 
HRSV glycoprotein (G) expression as a marker of infection in A549 
(left) or SH- SY5Y cells (right). Cells pretreated with NPPB (60 µM); DIDS 
(40 µM); R+IAA-94, (40 µM) or the known HRSV inhibitor ribavirin 
(60 µM) alongside solvent- treated controls (DMSO and H2O). GAPDH 
was probed as a loading control. DIDS, 4,4ʹ-diisothiocyanostilbene-2,2ʹ-
disulfonic acid; NPPB, 5- nitro-2-(3- phenylpropylamino) benzoic acid.
Figure 3 Inhibiting CFTR does not influence HRSV infection. (A–C) 
Number of HRSV- GFP expressing A549 cells treated with increasing 
concentrations of CFTR channel inhibitors CFTR(inh)-172 (10–25 µM), 
chromanol 293B (20–50 µM) or glibenclamide (10–40 µM), compared 
with DMSO- treated control cells (GFP count per well—black bars). Cell 
viability during each condition was determined via MTS assay (grey 
bars). Values are normalised to solvent control. Each experiment was 
performed in duplicate in 96- well plates and represents the average of 
four independent repeats (n=4)±SE. Statistical significance (p<0.05) is 
represented by an asterisk (*). (D) Representative IncuCyte images of 
HRSV- GFP- infected A549 cells treated with increasing concentrations 
of the CFTR channel inhibitors (left to right). Scale bar: 300 µm. CFTR, 
cystic fibrosis transmembrane conductance regulator; HRSV,human 
respiratory syncytial virus.
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TMEM16A is the CaCC required during HRSV infection
Within the two CaCC subfamilies (anoctamins and bestrophins), 
TMEM16A (anoctamin 1) is expressed in lung epithelial cells.23 
We used recently identified selective antagonists of TMEM16A; 
T16Ainh- A01 and MONNA,24 25 to assess their requirement 
during HRSV infection. Of note, we selected a pharmacological 
approach to target the Cl− functionality of TMEM16A, since 
gene- silencing approaches ablate the scaffolding and scram-
blase functions of this channel, leading to detrimental effects 
on cell growth.26 Cells were infected with HRSV- GFP in the 
presence of T16Ainh- A01 or MONNA (5–30 µM) and HRSV 
gene expression was assessed at 24 hpi. Figure 5A–C shows a 
significant reduction in HRSV- GFP expression in the presence of 
T16Ainh- A01 and MONNA that was confirmed by western blot 
analysis of WT- HRSV- treated cells (figure 5D). No cytotoxicity 
Figure 5 Modulation of TMEM16A decreases HRSV- GFP infection. 
(A–B) HRSV- GFP infection in A549 cells pretreated with TMEM16A- 
specific inhibitors T16Ainh- A01 (5–30 µM) and MONNA (5–30 µM) 
compared with solvent (DMSO) treated control cells (GFP count per 
well—black bars). Cell viability was determined via MTS assay (grey 
bars). Experiments were performed in duplicate and represent the 
average of four independent repeats (n=4) ±SE. Statistical significance 
is represented by an asterisk (*) where p<0.05. Values are normalised 
to solvent- treated controls. (C) Representative IncuCyte images in A549 
cells pretreated with increasing concentrations of TMEM16A- specific 
inhibitors (left to right) and infected with HRSV- GFP for 24 hours. Scale 
bar: 300 µm. (D) Western blot analysis of HRSV- G expression in A549 
cells treated with T16Ainh- A01 (20 µM); MONNA (20 µM) at 24 hpi. 
GAPDH was probed as a loading control. (E(i)). Representative western 
blot analysis of infection when HRSV virions were treated directly with 
CaCC inhibitors (CaCCinh- A01, 40 µM; T16Ainh- A01, 30 µM; MONNA, 
20 µM) or known HRSV inhibitor ribavirin, 40 µM, prior to infection of 
A549 cells. Treated viruses were diluted in media ≥400- fold to ensure 
no effects of the drugs on cells. HRSV infection was assessed by western 
blot analysis. (E(ii)). Densitometry of HRSV- G expression normalised to 
GAPDH loading controls. Data are the average of three independent 
repeats (n=3) and are shown as a percentage of solvent- treated 
controls (DMSO or H2O)±SE. (F) A549 cells were pretreated with the 
indicated CaCC inhibitors and infected with wild type HRSV at MOI 0.1 
(black), 0.5 (dark grey) and 1 (light grey). Data represent densitometric 
quantification of western blots from an average of three independent 
repeats±SE. CaCC, Ca2+- activated Cl− channel; HRSV,human respiratory 
syncytial virus.
Figure 4 CaCC blockers inhibit HRSV infection. (A) Targets of 
the broad- spectrum CaCC inhibitors CaCCinh- A01, niflumic acid, 
talniflumate and tannic acid assessed in the study. (B–E) HRSV- GFP 
expression in A549 cells pretreated with CaCCinh- A01 (5–40 µM), 
niflumic acid (10–40 µM), talniflumate (10–40 µM) and tannic acid 
(5–20 µM) (GFP count per well—black bars) compared with solvent 
(DMSO or H2O) treated cells. Cell viability was determined by MTS 
assays (grey bars). Treatments were performed in duplicate and 
represent the average of four independent repeats (n=4), ±SE. Values 
were normalised to solvent- treated controls. Statistical significance 
is represented by asterisk (*) where p<0.05. (F) Representative 
Incucyte images showing the decrease in HRSV- GFP expression in cells 
pretreated with increasing concentrations of CaCC inhibitors (left to 
right). (G–J) Western blot analysis showing wild type HRSV- G expression 
as a marker of HRSV infection in treated cells. GAPDH was probed 
as a loading control. CaCC, Ca2+- activated Cl− channel; HRSV,human 
respiratory syncytial virus.
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was observed at the inhibitory concentrations of each compound 
(figure 5A,B, grey bars). Importantly, we confirmed that the effects 
of T16Ainh- A01 and MONNA were cell mediated as the direct 
treatment of HRSV virions with T16Ainh- A01 and MONNA in 
the absence of cell treatment had no effect on HRSV infection 
(figure 5E). The inhibition of HRSV by these compounds was 
also independent of the MOI (figure 5F). We further confirmed 
that the requirement for TMEM16A was conserved during 
HRSV infection of SH- SY5Y cells, in which T16Ainh- A01 
(10–30 µM) and MONNA (20–40 µM) inhibited HRSV- GFP 
in a concentration- dependent manner (figure 6A,B,D). At the 
highest, non- toxic concentrations assessed, HRSV- GFP expres-
sion was reduced by 87% and 88%, respectively. Ribavirin treat-
ment led to a similar reduction in HRSV- GFP gene expression 
in this cell line (figure 6C,D). These data were confirmed by 
western blot analysis in which WT- HRSV- G expression was 
reduced following drug treatments (figure 6E) confirming the 
requirement for TMEM16A during HRSV infection.
TMEM16A is required during a postentry stage of HRSV 
infection
We next determined the HRSV life- cycle stage requiring 
TMEM16A functionality. HRSV- GFP gene expression can be 
detected at 9 hpi (figure 1A), suggesting at this timepoint that the 
virus had penetrated cells and already established viral replica-
tion complexes.19 27 The ability of a compound to inhibit HRSV 
when added 9 hpi would therefore be suggestive of activity at 
a postentry stage. In the experiments that followed, cells were 
infected with HRSV- GFP, each channel modulator was added 
at defined timepoints postinfection, and HRSV- GFP expression 
was analysed at 24 hpi. As expected, the addition of ribavirin 
at 0–6 hpi inhibited HRSV- GFP expression, consistent with its 
ability to inhibit RNA chain elongation and viral mRNA capping 
after cell entry (figure 7A). Consistent with previous studies,28 
the inhibition of endosomal acidification through the treatment 
of cells with ammonium chloride (NH4Cl) failed to impact 
HRSV- GFP (figure 7B). Treatment with tannic acid showed a 
large reduction when added prior to HRSV- GFP infection (0 
hpi) but showed reduced antiviral efficacy when added ≥3 hpi 
(figure 7C). This effect was consistent with the ability of this 
compound to prevent virus–receptor interactions as reported 
for HCV,29 HIV30 and norovirus,31 in addition to its effects 
Figure 6 TMEM16A blockers inhibit HRSV in neuronal cells. (A–C) 
Analysis of HRSV- GFP infection in SH- SY5Y (neuronal) cells pretreated 
with TMEM16A- specific inhibitors T16Ainh- A01 (10–30 µM) and 
MONNA (20–40 µM) and ribavirin (10–80 µM). Values are normalised 
to solvent- treated controls (DMSO or H2O) alongside cell viability 
assessments via MTS assays (grey bars). Data are the average of three 
independent repeats (n=3) ±SE. Statistical significance (p<0.05) are 
represented by an asterisk (*). (D) Representative IncuCyte images 
of HRSV- GFP expressing SH- SY5Y cells following CaCC channel 
modulation. Scale bars: 300 µm. (E) Western blot analysis of wild 
type HRSV- G expression in SH- SY5Y cells following treatment with 
T16Ainh- A01 (20 µM), MONNA (20 µM) or solvent (DMSO) control. 
GAPDH was probed as a loading control. CaCC, Ca2+- activated Cl− 
channel; HRSV,human respiratory syncytial virus.
Figure 7 CaCC inhibitors influence HRSV at a postentry stage of 
infection. (A–H) Time of addition assays in which A549 cells were 
infected with HRSV- GFP and treated with inhibitors at 0, 3, 6 or 
9 hours postinfection (hpi). HRSV- GFP expression was assessed at 24 
hpi. Ribavirin (40 µM) was included as positive control. NH4Cl (10 µM) 
was added to assess the effects of endosomal pH on virus infection. 
Inhibitor concentrations were as follows: NPPB (80 µM), CaCC inhibitors 
(tannic acid, 15 µM; CaCCinh- A01, 40 µM; talniflumate, 30 µM) and 
TMEM16A- specific inhibitors (T16ainh- A01, 30 µM; MONNA, 40 µM). 
Number of HRSV- GFP- expressing cells (GFP count per well) was 
normalised to solvent- treated cells (n=3)±SE. Statistical significance 
(p<0.05) are represented by an asterisk (*). CaCC, Ca2+- activated 
Cl− channel; HRSV,human respiratory syncytial virus; NPPB, 5- nitro-2-(3- 
phenylpropylamino) benzoic acid.
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on TMEM16A. Importantly, NPPB, CaCCinh- A01 and talni-
flumate (figure 7D–F), and the TMEM16A- specific inhibitors 
T16Ainh- A01 and MONNA (figure 7G,H) maintained their 
ability to inhibit HRSV when added up to 9 hpi. These data 
highlight TMEM16A modulators as inhibitors of the postentry 
stages of HRSV infection, thus showing promise as a postentry 
prophylaxis.
TMEM16A inhibits HRSV-induced IP-10 secretion in primary 
human lung tissue
TMEM16A is highly expressed in goblet cells, but it is also 
expressed to lower levels in the ciliated epithelium, where 
its silencing with short- interfering RNAs is known to block 
CaCC activity.32 This confirms that TMEM16A in ciliated 
epithelial cells (the major site of HRSV infection in the 
lungs) is the key mediator of Ca2+- dependent Cl− transport. 
We therefore investigated the effects of TMEM16A modu-
lation on HRSV infection in human PCLS as more physio-
logical models of virus infection. The PCLS system has been 
shown to support influenza A and rhinovirus (RV) infection 
in previous studies.33–35
In lung slices, actively replicating HRSV induces IP-10, 
whereas ultraviolet (UV)- inactivated virus is unable to increase 
IP-10 levels.33 We therefore investigated IP-10 as a surrogate 
marker for successful HRSV infection. Consistent with previous 
findings, we observed a significant increase in IP-10 secretion 
in PCLS infected with HRSV compared with UV- inactivated 
controls (figure 8A). Images of a PCLS airways infected with 
HRSV also showed specific HRSV staining and infection which 
co- localised with ciliated cells (figure 8B). These data validated 
the use of PCLS to further investigate the antiviral effects of 
TMEM16A inhibitors.
We found that the treatment of PCLS with T16Ainh- A01 
significantly reduced the HRSV- mediated release of IP-10 
(figure 8C).36 The addition of CaCCinh- A01 led to a similar 
decrease in IP-10 in 2/3 donors (online supplemental figure 
1Ai), yet these values did not reach statistical significance, 
most likely due to the lower specificity of this drug for 
TMEM16A. Both compounds showed no negative effects 
on PCLS integrity, confirmed through LDH release assays 
(≤30% vs Triton- lysed controls; figure 8D and online supple-
mental figure 1). T16Ainh- A01 treatment also led to a modest 
reduction in HRSV- G expression in the PCLS at 20 µM 
(figure 8E, representative blot) further confirmed through 
the assessment of HRSV- nucleoprotein (N) expression that 
similarly decreased following treatment with T16Ainh- A01 
(20 µM). These data confirmed that T16Ainh- A01 inhibits 
HRSV processes, particularly HRSV- mediated IP-10 release 
in more physiological models of HRSV infection. Given the 
known proinflammatory effects of IP-10,37 these data further 
reveal TMEM16A modulation as a potential target to subvert 
HRSV- mediated lung damage.
CaCCs may be required for other respiratory viruses
We finally investigated the sensitivity of IAV to TMEM16A modu-
lation. Cells were pretreated with CaCCinh- A01, TMEM16A- 
specific T16Ainh- A01 and MONNA, or ribavirin, and infected 
for 24 hours with IAV- GFP. We found that CaCCinh- A01 led to a 
small but significant decrease in IAV- GFP expression (figure 9A), 
while MONNA had minimal effects (figure 9B). Interestingly, 
T16Ainh- A01 treatment potently inhibited IAV- GFP expres-
sion (65% inhibition at 30 µM) compared with solvent controls 
(figure 9C,E). Ribavirin also showed activity against IAV 
(figure 9D,E). This may infer that IAV- GFP also depends on 
CaCCs, although those with a different pharmacological profile 
to HRSV.
DISCUSSION
The CaCC TMEM16A (anoctamin 1) and CFTR are the two 
major secretory anion channels in airway epithelia.38 TMEM16A 
is upregulated during airway inflammation and asthma and has 
been proposed as a drug target to compensate for abrogated 
CFTR function in patients with cystic fibrosis (CF).23 38 In this 
study, we showed that the targeted inhibition of TMEM16A, but 
not CFTR, is of potential therapeutic benefit to HRSV sufferers 
Figure 8 Modulation of TMEM16A in primary human lung tissue 
slices prevents HRSV- mediated IP-10 secretion. (A) Extrinsic IP-10 
levels in the supernatants of HRSV- infected or UV- inactivated PCLS. 
Samples were infected for 2 hours with 106 pfu/mL and extrinsic levels 
of IP-10 were measured in the supernatants at 72 hpi. Individual values 
(dots) of six independent donors are shown. Data were compared 
using an unpaired Mann- Whitney one- tailed test. p<0.05 (*). (B) 
Immunofluorescence image of HRSV- infected PCLS inoculated with 
106 pfu/mL HRSV for 2 hours. Slices were fixed 72 hpi and stained for 
HRSV (red), cilia (green) and DAPI (blue). (C) Extrinsic IP-10 in the 
supernatants of T16Ainh- A01 (10–20 µM) pretreated HRSV- infected 
PCLS 24 hpi. Values are the fold changes of cytokine values (normalised 
to pg/mg total protein) compared with respective untreated HRSV- 
infected tissue. Individual values (dots) of three donors are shown. 
Connecting lines represent data sets from the same donor. Data was 
analysed using an one- way ANOVA with Dunnett’s multiple comparison 
test p<0.05 (*) or <0.01 (**). (D) Released LDH is shown normalised 
to respective Triton- lysed untreated, uninfected tissue (n=3). Mean 
values (bars) and individual values (dots) of three donors are shown. 
(E) Representative western blot showing the expression of HRSV- G, 
HRSV- N and GAPDH (loading control) in PCLS samples treated with 
T16Ainh- A01. HRSV, human respiratory syncytial virus; LDH, lactate 
dehydrogenase; PCLS, precision- cut lung slices; UV, ultraviolet.
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through its ability to reduce viral gene expression and virus- 
induced IP-10 release when administered following HRSV infec-
tion. We therefore highlight TMEM16A inhibitors as a novel 
postexposure prophylaxis for HRSV, which may be conserved 
for other important respiratory virus infections.
TMEM16A is unique among Cl− channels as it comprises a 
dual function scramblase39 that is frequently amplified in human 
cancers.40 As TMEM16A silencing approaches are detrimental 
to cancer cell growth,26 our cell culture studies were limited to 
pharmacological inhibition of the Cl− functional component of 
the channel, which was not detrimental to cell health,26 vali-
dated in both cell lines and human PCLS. Indeed, and as previ-
ously reported, TMEM16A silencing using siRNA in our hands 
led to a loss of cell proliferation in A549 cells (data not shown), 
confirming that a reduction of TMEM16A protein but not 
functionality induces growth defects. An additional benefit of 
the pharmacological approach was that time- of- addition assays 
could be performed, revealing that TMEM16A- specific inhibi-
tors maintained their inhibitory effects on HRSV when added 
9 hpi, the time when viral gene expression and viral assembly/
release would have already been initiated.19 This suggested that 
HRSV requires TMEM16A function for postentry stages of the 
virus life- cycle.
An unanswered question remains as to why HRSV is influ-
enced by TMEM16A Cl− channel functionality. TMEM16A is 
essential for the activation of CFTR,21 however, CFTR blockers 
had no effect on HRSV infection, suggesting a role indepen-
dent of this relationship. Similarly, the lack of NH4Cl sensitivity 
during any stage of the HRSV life- cycle suggested no direct role 
of Cl− as a counter- ion for H+ through TMEM16A.41 A finding 
of note was that HRSV- induced IP-10 release could be inhib-
ited by TMEM16A blockers in PCLS. Given that proinflam-
matory cytokine secretion is suppressed by TMEM16A activity 
in human cystic fibrosis bronchial epithelia,42 this suggests that 
the specific effects of TMEM16A modulation on this inflam-
matory cytokine are likely mediated through the perturbation 
of HRSV- mediated processes, including virus replication and/
or assembly and release. However, direct IP-10 modulation 
by TMEM16A may represent a limitation of this assay, which 
requires assessment in future studies. The organisation, compo-
sition and functions of replication factories induced by RNA 
viruses are generally accepted to require the recruitment of a 
range of host cell factors.43 Anion channels are important in a 
range of these viral replicase systems; CHIKV is dependent on 
CLIC1 that interacts with NSP3, a known component of the 
replicase complex12; the voltage- dependent anion channel 1 
directly interacts with VP1 and VP3 of infectious bursal disease 
virus, a member of the Birnaviridae to stabilise RNP formation44; 
and CLIC-1, ClC-5 and ClC-7 silencing impede HCV replica-
tion.13 Of interest, inclusion body- associated granules (IBAGs) 
are key to HRSV RNA synthesis and contain viral mRNA and 
the viral protein M2-1, but exclude viral genomes and all neces-
sary components required for transcription and replication (N, P 
and L).27 IBAGs are related to aggresomes, the sites for the accu-
mulation of dead- end protein products in response to ER stress 
responses.45 Interestingly, aggresomes are known to be induced 
by TMEM16A activity.40 Further studies will dissect any role of 
TMEM16A in these HRSV- induced processes.
In summary, and for the first time, we implicate host cell Cl− 
conductances through TMEM16A as a key cellular process that 
is required during HRSV replication. The challenge is now to 
define the specific HRSV functionality that requires TMEM16A 
and regulates IP-10 release, and to assess the effectiveness of 
TMEM16A modulators as in vivo anti- HRSV drugs.
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Supplemental figure legends 
Supplementary Figure 1. CaCCinh-A01 inhibits HRSV in primary human lung tissue. A)i 
Extrinsic IP-10 in the supernatants of CaCCinh-A01 (10–20 µM) pre-treated HRSV-infected PCLS 
24 hpi. Values are the fold changes of cytokine values (normalised to pg/mg total protein) compared 
tocompared with respective untreated HRSV-infected tissue. Individual values (dots) of three 
independent donors are shown. Connecting lines represent data sets at different drug concentration 
from the same donor. A one-way ANOVA with Dunnett’s multiple comparison test was used for 
statistical analysis. P-values<0.05 (*) or <0.01 (**) were considered significant. A)ii. Released 
LDH normalised to respective Triton-lysed untreated, uninfected tissue (n=3). Mean values (bars) 
and individual values (dots) of three donors are given. NS: non-significant differences. 
Supplementary Figure 2. Statistical analysis. Total green object count (1/well), average 
integrated intensity (GCU x µm2) and western blot densitometry data were compared using a one-
way ANOVA Bonferroni multiple comparison test. The model was verified using the HRSV 
inhibitor ribavirin. P-values≤0.05 were considered statistically significant (*) and are shown in 
bold. PCLS analysis was performed using an unpaired Mann Whitney one-tailed test or one-way 
ANOVA Dunnett’s multiple comparison test. 
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Figure S2. Statistical analysis 
NB - bold P value < 0.05 *
[Ribavirin] (µM) HRSV infection (n=4) ± SEM P-value
Fig 1C (i) Mock 0% 0%
H2O 100% 0%
10 64% 13% 0.056575291
20 48% 22% 0.014637204
40 27% 11% 9.12565E-05
80 7% 4% 8.76743E-08
[DIDS] (µM) HRSV infection (n=3) ± SEM P-value
Fig 2A Mock 0% 0%
DMSO 100% 0%
10 38% 16% 0.01849495
20 28% 10% 0.002247572
30 23% 9% 0.001244719
40 17% 5% 6.29142E-05
50 14% 4% 4.41482E-05
[NPPB] (µM) HRSV infection (n=4) ± SEM P-value
Fig 2B Mock 0% 0%
DMSO 100% 0%
40 57% 4% 4.46039E-05
60 35% 6% 3.03231E-05
80 15% 3% 1.59212E-07
100 5% 2% 4.14935E-09
[R+IAA-94] (µM) HRSV infection (n=3) ± SEM P-value
Fig 2C Mock 0% 0%
DMSO 100% 0%
10 89% 10% 0.334510806
15 97% 8% 0.699962848
20 105% 8% 0.605070188
25 92% 1% 0.000125389
[CFTR(inh)-172] (µM) HRSV infection (n=3) ± SEM P-value
Fig 3A Mock 0% 0%
DMSO 100% 0%
10 95% 4% 0.267042416
15 83% 18% 0.37752906
20 84% 13% 0.274045678
25 91% 3% 0.054221636
[Chromanol 293B] (µM) HRSV infection (n=3) ± SEM P-value
Fig 3B Mock 0% 0%
DMSO 100% 0%
20 96% 2% 0.148440081
30 113% 2% 0.00124868
40 108% 6% 0.248905321
50 111% 5% 0.083345039
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[Glibenclamide] (µM) HRSV infection (n=3) ± SEM P-value
Fig 3C Mock 0% 0%
DMSO 100% 0%
10 84% 11% 0.19888495
20 99% 7% 0.933901547
30 92% 27% 0.781366014
40 90% 24% 0.6955903
[CaCCinh-A01] (µM) HRSV infection (n=4) ± SEM P-value
Fig 4B Mock 0% 0%
DMSO 100% 0%
5 83% 5% 0.01106311
10 81% 6% 0.01513399
20 70% 8% 0.008862589
30 58% 8% 0.001907044
40 40% 10% 0.001084016
[Niflumic acid] (µM) HRSV infection (n=4) ± SEM P-value
Fig 4C Mock 0% 0%
DMSO 100% 0%
10 74% 8% 0.017043297
20 49% 4% 7.12008E-06
30 26% 3% 7.34332E-07
40 6% 2% 6.07815E-09
[Talniflumate] (µM) HRSV infection (n=4) ± SEM P-value
Fig 4D Mock 0% 0%
DMSO 100% 0%
10 84% 7% 0.068624187
20 60% 4% 0.000106183
30 45% 7% 0.000271721
40 25% 10% 0.000253502
[Tannic acid] (µM) HRSV infection (n=4) ± SEM P-value
Fig 4E Mock 0% 0%
DMSO 100% 0%
5 102% 22% 0.943551776
10 60% 16% 0.043897183
15 23% 4% 1.60841E-06
20 9% 6% 3.55868E-06
[T16Ainh-A01] (µM) HRSV infection (n=4) ± SEM P-value
Fig 5A Mock 0% 0%
DMSO 100% 0%
5 103% 6% 0.637873932
10 84% 7% 0.063298134
20 30% 11% 0.000624893
30 21% 10% 0.000225154
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[MONNA] (µM) HRSV infection (n=4) ± SEM P-value
Fig 5B Mock 0% 0%
DMSO 100% 0%
5 101% 6% 0.856907048
10 89% 5% 0.0633896
20 78% 4% 0.001902963
30 34% 11% 0.000914403
Drug treatment Norm HRSV-G (n=3) ± SEM P-value
Fig 5E (ii) Mock 0% 0%
DMSO 100% 0%
H2O 100% 0%
Ribavirin 84% 14% 0.31645321
CaCCinh-A01 120% 26% 0.482665103
T16Ainh-A01 133% 22% 0.210016952
MONNA 137% 32% 0.31072787
Fig 5F
CaCCinhA01 T16AinhA01 MONNA Ribavirin
MOI 0.1 3.74853E-05 2.84969E-05 0.005330362 0.011855105
MOI 0.5 0.000158912 5.30424E-05 0.001419678 0.006063957
MOI 1 3.17979E-05 8.68031E-06 0.006981707 0.002502494
Fig 6A [T16Ainh-A01] (µM) HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
10 88% 7% 0.145793651
20 38% 8% 0.001159807
30 13% 5% 7.02817E-05
Fig 6B [MONNA] (µM) HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
20 45% 5% 0.000302672
40 12% 3% 7.60573E-06
Fic 6C [Ribavirin] (µM) HRSV infection (n=3) ± SEM P-value
Mock 0 0
DMSO 0.999999986 1.41077E-08
10 0.793859886 0.152074392 0.24673625
20 0.712999902 0.06785377 0.013373424
40 0.420317382 0.121162206 0.008747625
80 0.148258481 0.080015786 0.000441055
P-value (vs solvent control)
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Fig 7A Ribavirin treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 15% 3% 5.40812E-06
3 hpi 28% 4% 4.1061E-05
6 hpi 41% 9% 0.003327383
9 hpi 63% 7% 0.005205526
Fig 7B Ammonium chloride HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 97% 2% 0.138090734
3 hpi 94% 3% 0.138696548
6 hpi 89% 6% 0.133932782
9 hpi 94% 6% 0.419262133
Fig 7C Tannic acid treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 8% 4% 2.77441E-05
3 hpi 61% 3% 0.000172151
6 hpi 73% 7% 0.01534855
9 hpi 87% 2% 0.001317721
Fig 7D NPPB treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 13% 4% 3.89241E-05
3 hpi 20% 7% 0.000376239
6 hpi 18% 6% 0.000127559
9 hpi 31% 5% 0.000205059
Fig 7E CaCCinh-A01 treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 19% 6% 0.000170113
3 hpi 24% 3% 1.48547E-05
6 hpi 25% 5% 0.000116391
9 hpi 37% 2% 4.44583E-06
Fig 7F Talniflumate treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 36% 8% 0.001252441
3 hpi 51% 4% 0.000164702
6 hpi 53% 8% 0.004552312
9 hpi 60% 8% 0.008682141
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Fig 7G T16Ainh-A01 treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 5% 0% 4.57043E-09
3 hpi 15% 6% 0.000177506
6 hpi 10% 3% 1.31226E-05
9 hpi 20% 4% 2.95555E-05
Fig 7H MONNA treatment HRSV infection (n=3) ± SEM P-value
Mock 0% 0%
H2O 100% 0%
0 hpi 4% 2% 3.68733E-07
3 hpi 3% 1% 2.22248E-07
6 hpi 7% 3% 5.48394E-06
9 hpi 16% 4% 2.29817E-05
Fig 9A [CaCCinh-A01] (µM) IAV infection (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
5 70% 6% 0.006236804
10 70% 5% 0.002749688
20 74% 5% 0.00685923
30 83% 6% 0.042960933
40 87% 7% 0.122621862
Fig 9B [MONNA] (µM) IAV infection (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
5 73% 9% 0.04495508
10 70% 12% 0.069097746
20 64% 11% 0.028466599
30 80% 17% 0.296029284
Fig 9C [T16Ainh-A01] (µM) IAV infection (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
5 72% 7% 0.018653604
10 57% 7% 0.003559684
20 38% 6% 0.000436407
30 35% 5% 0.000167838
Fig 9D [Ribavirin] (µM) Average % IAV (n=3) ± SEM P-value
Mock 0% 0%
DMSO 100% 0%
10 75% 7% 0.029274925
20 74% 13% 0.112477732
40 58% 10% 0.012958989
60 14% 3% 8.14213E-06
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PCLS: IP-10 
Fig 8A Treatment P-value
UV vs untreated virus 0.0043
Fig 8C [T16Ainh-A01] (µM) IP-10  fold change (n=3) ± SEM P-value
Mock 1 0 -
10 0.35 20.26 0.0152
20 0.07 3.87 0.0027
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